Farallon Capital Management, L.L.C.

Institutional investor · Portfolio as of Q2 2026

Q2 2026 biggest moves
  • MSFTMSFT

    Microsoft

    Cut 53%

    now 2.2% of stocks

  • SCHWSCHW

    Charles Schwab

    Sold out

    was 2.0% of stocks

  • AONAON

    Aon

    Cut 45%

    now 2.5% of stocks

  • IMVTIMVT

    Immunovant

    3.8× the shares

    now 1.2% of stocks

179 changes in all

Top Holdings92 positions

Checking export access…
Activity:
SPY
SPY
PUT

STATE STR SPDR S&P 500 ETF T

6M$4.5B19.4%———
New
—
RVMD

Revolution Medicines, Inc.

13.6M$2.5B11.0%$35.31+430.35%
22 qtrssince 2021-Q1
Decreased
0
EA
EADelisted

ELECTRONIC ARTS INC

7.9M$1.6B7.0%——
3 qtrssince 2025-Q4
Increased
66
BBIO

BridgeBio Pharma, Inc.

10.7M$800.1M3.5%$43.29+72.03%
8 qtrssince 2024-Q3
Increased
67
PTGX

Protagonist Therapeutics, Inc.

6.3M$778.2M3.4%$22.07+455.37%
31 qtrssince 2018-Q4
Unchanged
0
WBD
WBDDelisted

WARNER BROS DISCOVERY INC

28.1M$749.1M3.3%——
3 qtrssince 2025-Q4
Increased
58
EXEL

Exelixis, Inc.

13.5M$732.8M3.2%$24.12+125.57%
31 qtrssince 2018-Q4
Increased
60
LQDA

Liquidia Corporation

8.4M$666.9M2.9%$18.21+337.93%
10 qtrssince 2024-Q1
Decreased
0
AMZN

Amazon.com, Inc.

2.6M$627.5M2.7%$221.93+7.39%
5 qtrssince 2025-Q2
Decreased
0
LNTH

Lantheus Holdings, Inc.

5.6M$619.4M2.7%$78.36+41.59%
14 qtrssince 2023-Q1
Unchanged
0
NTRA

Natera, Inc.

2.2M$602.2M2.6%$74.59+263.92%
21 qtrssince 2021-Q2
Decreased
0
UNH

UnitedHealth Group Incorporated

1.3M$528.1M2.3%$412.83+0.06%
14 qtrssince 2023-Q1
Decreased
0
TMO

Thermo Fisher Scientific Inc

1M$526M2.3%$468.64+6.90%
27 qtrssince 2019-Q4
Increased
63
ROIV

Roivant Sciences Ltd.

14.3M$506.4M2.2%$30.15+17.39%
13 qtrssince 2023-Q2
Increased
74
KVUE
KVUEDelisted

KENVUE INC

25M$478M2.1%$16.47+13.41%
3 qtrssince 2025-Q4
Decreased
0
AON

Aon plc

1.4M$458.6M2.0%$328.37+0.53%
10 qtrssince 2024-Q1
Decreased
0
BSX

Boston Scientific Corporation

10.5M$449M1.9%$64.74-34.08%
24 qtrssince 2020-Q3
Increased
66
AVGO

Broadcom Inc.

1.2M$435.1M1.9%$326.38+15.53%
3 qtrssince 2025-Q4
Decreased
0
MSFT

Microsoft Corporation

1.1M$415.1M1.8%$339.51+9.45%
31 qtrssince 2018-Q4
Decreased
0
TNGX

Tango Therapeutics, Inc.

12.3M$383.8M1.7%$12.09+158.65%
7 qtrssince 2024-Q4
Increased
63
$18.5B
In stocks
89
Stock positions
Q2 2026
Filing
HI rating · 1.0/5
Quarterly Equity Value Change
Value in stocks ($B)
Values in stocks and quarter-over-quarter equity value changes; not investment returns.
QuarterValue in stocks in US dollarsEquity value change
2025-Q1$18,545,443,566-2.26953660008%
2025-Q2$21,931,414,19818.2576955895%
2025-Q3$17,697,530,560-19.3051100115%
2025-Q4$20,286,847,44114.6309501895%
2026-Q1$18,264,563,543-9.96844829578%
2026-Q2$18,451,268,9201.02222742175%
Activity profile
$ moved · Q2'26
New33%Increased15%Decreased22%Exited30%
Composition
Equity vs derivatives
Equity80%Puts20%Calls<1%
Holding period
Avg 2.4 years
<1Q22%1-4Q23%1-2Y10%2Y+46%

Farallon Capital Management, L.L.C. holds $18.5B in stocks across 89 positions as of Q2 2026. Top stock holdings: RVMD, EA, BBIO. Largest options: SPY puts. Fund DNA: Balanced Allocator. HoldingsIntel Score: 1/5.0.

Top holdings by portfolio weight

Total AUM$18B
RVMD11.01%
EA7.05%
BBIO3.47%
PTGX3.38%
WBD3.25%
EXEL3.18%
LQDA2.89%
AMZN2.72%
LNTH2.69%
NTRA2.61%
Other2.29%

Portfolio allocation by GICS sector

Sectors10
Healthcare65.48%
Communication Services14.14%
Technology6.80%
Financial Services4.73%
Consumer Cyclical3.51%
Consumer Defensive2.63%
Industrials2.46%
Basic Materials0.24%
Energy0.01%
Real Estate0.00%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare, Communication Services
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L34
Conviction61
Concentration69
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
8Q
BBIOBBIOBridgeBio Pharma, Inc.
Q4 2024 → Q3 2026+12.5M shares+$893M
6Q
BSXBSXBoston Scientific Corporation
Q2 2025 → Q3 2026+7.5M shares+$113.1M
3Q
AGIOAGIOAgios Pharmaceuticals, Inc.
Q1 2026 → Q3 2026+779,895 shares+$57M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used